Inhibiting PIM2 sensitizes CML to Gleevec

DISEASE CATEGORY: Cancer

INDICATION: Chronic myelogenous leukemia (CML)

Patient sample, cell culture and mouse studies suggest inhibiting PIM2 could sensitize CML to the dual BCR-ABL/c-Kit inhibitor Gleevec imatinib. In

Read the full 276 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE